Company logo

VSTM - Verastem, Inc.

NASDAQ -> Healthcare -> Biotechnology
Needham, United States
Type: Equity

VSTM price evolution
VSTM
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $78.15 $95.23 $183.33 $97.5
Short term investments $59.22 $70.68 $13.94
Net receivables $0
Inventory
Total current assets $143.68 $174.49 $189.96 $118.89
Long term investments
Property, plant & equipment $1.21 $1.37 $1.53 $1.71
Goodwill & intangible assets
Total noncurrent assets $6.04 $1.67 $1.79 $1.98
Total investments $59.22 $70.68 $13.94
Total assets $149.72 $176.15 $191.76 $120.88
Current liabilities
Accounts payable $7.18 $5.12 $4.55 $4.9
Deferred revenue
Short long term debt $0.94 $1.34 $1.73 $2.12
Total current liabilities $26.38 $23.81 $20.79 $22.36
Long term debt $40.62 $40.69 $40.76 $40.82
Total noncurrent liabilities $44.8 $48 $48.22 $44.33
Total debt $41.56 $42.04 $42.49 $42.94
Total liabilities $71.19 $71.81 $69.01 $66.69
Shareholders' equity
Retained earnings -$824.89 -$797.52 -$777.52 -$753.24
Other shareholder equity $0.01 $0.05 $0 $0.01
Total shareholder equity $57.37 $83.18 $101.59 $33.02
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $78.15 $75.17 $21.49 $68.02
Short term investments $59.22 $12.96 $79 $73.44
Net receivables $0.03 $0.52 $0.24
Inventory
Total current assets $143.68 $92.87 $105.74 $144.94
Long term investments $6
Property, plant & equipment $1.21 $1.88 $2.51 $3.14
Goodwill & intangible assets
Total noncurrent assets $6.04 $2.18 $2.92 $9.41
Total investments $59.22 $12.96 $79 $79.44
Total assets $149.72 $95.05 $108.66 $154.35
Current liabilities
Accounts payable $7.18 $4.9 $2.3 $1.88
Deferred revenue
Short long term debt $0.94 $1.07 $0.67 $0.56
Total current liabilities $26.38 $21.66 $18.59 $17.09
Long term debt $40.62 $24.53 $2.51 $21.98
Total noncurrent liabilities $44.8 $26 $2.51 $21.98
Total debt $41.56 $27.07 $3.18 $22.54
Total liabilities $71.19 $47.66 $21.1 $39.08
Shareholders' equity
Retained earnings -$824.89 -$737.52 -$663.71 -$592.51
Other shareholder equity $0.01 $0.03 $0.05
Total shareholder equity $57.37 $47.39 $87.56 $115.27
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $22.5 $13.95 $12.89 $12.02
Selling, general & administrative $8.64 $7.36 $7.4 $7.33
Total operating expenses $31.14 $21.31 $20.29 $19.34
Operating income -$31.14 -$21.31 -$20.29 -$19.34
Income from continuing operations
EBIT -$26.25 -$18.88 -$23.16 -$14.95
Income tax expense
Interest expense $1.12 $1.13 $1.12 $0.77
Net income
Net income -$27.37 -$20 -$24.28 -$15.71
Income (for common shares) -$27.37 -$20 -$24.28 -$15.71
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $2.6 $2.05 $88.52
Cost of revenue $33.74
Gross Profit $2.6 $2.05 $54.77
Operating activities
Research & development $61.36 $50.56 $39.35 $41.38
Selling, general & administrative $30.73 $24.98 $24.11 $62.76
Total operating expenses $92.08 $75.53 $63.46 $104.13
Operating income -$92.08 -$72.94 -$61.41 -$49.36
Income from continuing operations
EBIT -$83.23 -$71.67 -$61.23 -$51.74
Income tax expense $0.19
Interest expense $4.14 $2.14 $9.97 $15.79
Net income
Net income -$87.37 -$73.81 -$71.2 -$67.73
Income (for common shares) -$87.37 -$73.81 -$71.2 -$67.73
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$27.37 -$20 -$24.28 -$15.71
Operating activities
Depreciation -$0.04 -$0.04 -$0.02 -$0.01
Business acquisitions & disposals
Stock-based compensation $1.6 $1.52 $1.43 $1.31
Total cash flows from operations -$29.68 -$16.59 -$19.9 -$20.29
Investing activities
Capital expenditures
Investments $12.44 -$70.08 $14 -$0.8
Total cash flows from investing $12.44 -$70.08 $14 -$0.8
Financing activities
Dividends paid
Sale and purchase of stock -$0.46 $91.91 $0.03
Net borrowings -$0.45 -$0.43 -$0.42 $15.92
Total cash flows from financing -$0.45 -$0.89 $91.48 $44.05
Effect of exchange rate
Change in cash and equivalents -$17.69 -$87.56 $85.58 $22.96
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$87.37 -$73.81 -$71.2 -$67.73
Operating activities
Depreciation -$0.11 -$0.04 $0.07 $0.46
Business acquisitions & disposals
Stock-based compensation $5.86 $6.05 $7.71 $8.12
Total cash flows from operations -$86.46 -$63.67 -$53.5 -$33.51
Investing activities
Capital expenditures -$0.2 -$0.03
Investments -$44.45 $66.19 $0.28 -$47.33
Total cash flows from investing -$44.45 $66.19 $0.09 -$47.36
Financing activities
Dividends paid
Sale and purchase of stock $91.48 $27.64 $7.81 $109.04
Net borrowings $14.62 $24.15 -$39.13
Total cash flows from financing $134.19 $51.78 $6.88 $69.63
Effect of exchange rate
Change in cash and equivalents $3.29 $54.3 -$46.53 -$11.24
News
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc
GuruFocus.com via Yahoo Finance 15 Feb 2024
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
GuruFocus.com via Yahoo Finance 7 Feb 2024
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Zacks via Yahoo Finance 24 Jan 2024
Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss
Simply Wall St. via Yahoo Finance 2 May 2023
individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM)...
Simply Wall St. via Yahoo Finance 11 Jan 2023
10 Long-Term Stocks to Buy During Recessions
Insider Monkey via Yahoo Finance 19 Sep 2022
Investors five-year losses grow to 64% as the stock sheds US$34m this past week
Simply Wall St. via Yahoo Finance 23 Aug 2022
Is Verastem (NASDAQ:VSTM) Using Too Much Debt?
Simply Wall St. via Yahoo Finance 9 Aug 2022
What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition
Simply Wall St. via Yahoo Finance 27 Jun 2022
7 Cheap Biotech Stocks to Buy Now
InvestorPlace via Yahoo Finance 20 May 2022
Fundamentals
Market cap $299.58M
Enterprise value $262.99M
Shares outstanding 25.28M
Revenue $0.00
EBITDA -$83.34M
EBIT -$83.23M
Net Income -$87.37M
Revenue Q/Q N/A
Revenue Y/Y -100.00%
P/E ratio -3.43
EV/Sales N/A
EV/EBITDA -3.16
EV/EBIT -3.16
P/S ratio N/A
P/B ratio 5.22
Book/Share 2.27
Cash/Share 3.09
EPS -$3.46
ROA -54.73%
ROE -127.00%
Debt/Equity 1.24
Net debt/EBITDA 0.08
Current ratio 5.45
Quick ratio 5.45